Surgical vs Transcatheter Aortic Valve Replacement in YOUNG Patients
Surgical Bioprosthesis Aortic Valve Replacement Vs. Myval Balloon-Expandable THV Series in Patients Aged 65 to 75 With Symptomatic Severe Aortic Stenosis Judged Eligible by Heart Team
Ceric Sàrl
1,180 participants
May 15, 2025
INTERVENTIONAL
Conditions
Summary
The study objective is to demonstrate that the clinical outcomes of the Myval balloon-expandable THV series are non-inferior to those of SAVR in patients with symptomatic severe aortic stenosis aged 65 to 75 years.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients receive Myval balloon-expandable THV Series (TAVR)
Patients receive any surgical bioprosthetic valve commercially available at the clinical investigation site (SAVR)
Locations(49)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06861361